BP1.4979 is a selective dopamine D<sub>3</sub> receptor agonist which is under development for the treatment of binge-eating disorder, obsessiveâÂÂcompulsive disorder (OCD), restless legs syndrome (RLS), and smoking withdrawal. It is taken orally. The drug acts as a highly potent weak partial agonist of the dopamine D<sub>3</sub> receptor (K<sub>i</sub> = ~1nM; = 0.7nM; = 32%). It has around 200-fold higher affinity for the dopamine D<sub>3</sub> receptor than for the dopamine D<sub>2</sub> receptor (K<sub>i</sub> = 192nM), where it is an antagonist. BP1.4979 showed 66% dopamine D<sub>3</sub> receptor occupancy and 8% dopamine D<sub>2</sub> receptor occupancy with positron emission tomography (PET) imaging in a clinical study. The time to peak levels of BP1.4979 is 1hour and its elimination half-life is about 8hours. The drug is under development by Bioprojet. As of January 2026, it is in phase 2 clinical trials for all indications.